Assert-IQ vs Imbio PHA (4.0.0)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

Imbio PHA (4.0.0)

by Imbio (a subsidiary of 4DMedical)

AI Verdict

Assert-IQ is an insertable cardiac monitor focused on long-term, continuous electrical activity monitoring for arrhythmia detection and management. In contrast, Imbio PHA is AI-powered software that analyzes CT pulmonary angiogram scans to measure cardiac structures for the diagnosis and risk stratification of pulmonary embolism and hypertension. While both utilize AI in cardiology, their distinct data sources (electrical signals vs. medical images) and primary clinical applications make them complementary rather than directly competitive tools.

Choose Assert-IQ if…

Choose Assert-IQ if your patients require long-term, continuous cardiac monitoring for up to six years to detect and manage suspected arrhythmias. This system is ideal for comprehensive, remote surveillance of heart rhythm disorders, providing proactive alerts and patient-activated symptom logging for a complete diagnostic picture.

View Assert-IQ →

Choose Imbio PHA (4.0.0) if…

Choose Imbio PHA (4.0.0) if you need rapid, AI-powered automated analysis of CT pulmonary angiogram (CTPA) scans to assess cardiac structures. This tool is best suited for quickly measuring ventricular and arterial diameters and ratios, aiding in the diagnosis and risk stratification of conditions like pulmonary embolism and hypertension.

View Imbio PHA (4.0.0) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	Imbio PHA (4.0.0)
Deployment	Subcutaneously implanted device with mobile app connectivity	Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Imbio PHA (4.0.0)

Imbio PHA integrates seamlessly into existing radiology workflows by generating annotated DICOM images and PDF reports, offering rapid, automated assessment within minutes. This direct integration streamlines diagnostic tasks for clinicians. Assert-IQ's usability is more focused on patient interaction for long-term remote monitoring.

Clinical Value

Assert-IQ

Assert-IQ provides long-term, continuous cardiac monitoring for up to 6 years with advanced arrhythmia detection algorithms and proactive clinician alerts. This extended, continuous data collection offers profound clinical value for diagnosing and managing elusive heart rhythm disorders that might otherwise be missed. Imbio PHA offers valuable rapid, quantitative assessment from CT scans for acute conditions.

Pricing & Value

Tie

Both tools are enterprise-level solutions requiring direct contact for pricing details, and neither offers a free trial. Without specific pricing information or publicly available cost-benefit analyses, it is impossible to definitively compare their value propositions.

Enterprise Readiness

Imbio PHA (4.0.0)

Both tools are FDA-cleared and HIPAA compliant, targeting large healthcare systems. Imbio PHA explicitly mentions flexible deployment options including Cloud, Enterprise (on-premise), or via partners, demonstrating a broader readiness for diverse IT infrastructures compared to Assert-IQ's 'hybrid' deployment.

Innovation

Assert-IQ

Assert-IQ's innovation lies in its ability to provide continuous cardiac monitoring for an extended period of up to 6 years, coupled with advanced AI algorithms for arrhythmia detection and remote patient management capabilities. This represents a significant advancement in long-term cardiac diagnostics and patient care. Imbio PHA's innovation is in applying AI to automate specific image measurements.

Support & Docs

Assert-IQ

Abbott provides comprehensive support for Assert-IQ, including extensive clinician and patient manuals, dedicated 24-hour phone lines for technical support, and email support. While Imbio PHA offers user manuals and email support for malfunctions, Abbott's range of support resources appears more robust and readily accessible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	Imbio PHA (4.0.0)
Name	Assert-IQ	Imbio PHA (4.0.0)
Description	Long-term, continuous monitoring and advanced arrhythmia detection for suspected heart rhythm disorders.	AI-powered medical image processing software for measuring cardiac structures from CTPA scans to assess right ventricular dilation and aid in diagnosis/risk stratification of pulmonary embolism and hypertension.
Company	Abbott Medical	Imbio
Key Functionality	Long-term continuous cardiac monitoring (up to 6 years), advanced arrhythmia detection, remote monitoring.	Automated measurement of right/left ventricle and main pulmonary artery/aorta diameters, calculates RV/LV and PA/Ao ratios, generates annotated DICOM images.
Categories	Cardiology AI, Clinical Decision Support & Reference	Cardiology AI, Radiology & Imaging AI
Specialties	Cardiology, Internal Medicine	Cardiology, Pulmonology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and Imbio PHA (4.0.0).

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications for Assert-IQ and Imbio PHA (4.0.0)?

Assert-IQ is an insertable cardiac monitor designed for long-term, continuous monitoring and advanced arrhythmia detection to aid in diagnosing and managing patients with suspected heart rhythm disorders. Imbio PHA (4.0.0) is an AI-powered medical image processing software that analyzes CT pulmonary angiogram (CTPA) scans to measure cardiac structures, assessing potential right ventricular dilation to aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.

How do these tools acquire and process patient data?

Assert-IQ acquires data through a minimally invasive insertable cardiac monitor, which provides long-term continuous cardiac monitoring and transmits data via Bluetooth Low Energy to a secure cloud-based platform. Imbio PHA (4.0.0) processes existing CT pulmonary angiogram (CTPA) scans using artificial intelligence algorithms for automated anatomical identification and measurement.

Which medical specialties are these tools primarily intended to support?

Assert-IQ is designed to support Cardiology and Internal Medicine specialties. Imbio PHA (4.0.0) is intended for use by Cardiology, Pulmonology, and Radiology specialists.

What specific types of data or insights do Assert-IQ and Imbio PHA (4.0.0) provide to clinicians?

Assert-IQ provides long-term continuous cardiac monitoring data, advanced arrhythmia detection, remote monitoring capabilities, and proactive clinician alerts, including patient-activated symptom logging. Imbio PHA (4.0.0) provides automated measurements of right and left ventricle diameters, main pulmonary artery and aorta diameters, calculated RV/LV and PA/Ao ratios, annotated DICOM images, and summary reports in PDF format.

What is the typical timeframe for data collection or assessment with each tool?

Assert-IQ provides long-term continuous cardiac monitoring for up to 6 years, with options for at least three or six years of battery life. Imbio PHA (4.0.0) offers rapid, fully-automated assessment of CTPA scans, typically generating results in minutes.